Submitted:
22 November 2024
Posted:
26 November 2024
You are already at the latest version
Abstract
Literature associating the spread of SARS-CoV-2 with the healthcare-related, geographical and demographic characteristics of the territory, is inconclusive and contrasting. We studied these relationships during winter 2021/22 in South Tyrol, a multicultural Italian alpine province, performing an ecological study based on the 20 districts of the area. Data about incidence, hospitalization, and death between November ‘21 and February ‘22 was collected and associated to territorial variables via bivariate analyses and multivariate regressions. Both exposure variables and outcomes varied widely among districts. Incidence was found to be mainly predicted by vaccination coverage (negative correlation). Mortality and ICU admission rates partially followed this distribution, while case fatality rate was inversely correlated to average salary, and hospital admission rates increased where hospitals capacity was higher, and from the southern to the northern border of the province. These findings, besides confirming the efficacy of vaccination in preventing both new and severe SARS-CoV-2 cases, highlight that several geographical and socio-demographic variables can be related to disease epidemiology. Remote areas with wage gaps and lower access to care suffered most the pandemic. Our findings, therefore, underly the existence of health inequity issues that need to be targeted by implementing specifically tailored public health interventions.
Keywords:
1. Introduction
2. Materials and Methods
2.1. Exposure Variables
2.2. Outcome Variables
- SARS-CoV-2 cases: a total number of all new cases occurred among resident population between 1st November 2021 and 12th February 2022. To this category belong all patients who had taken a diagnostic swab with a positive result in any authorised centre of the province without a recorded positive result in the previous 90 days [22).
- Hospitalisations: total number hospitalisation related to the SARS-CoV-2 cases occurring up to 21 days (lastly up to 4th March 2022) after diagnosis. Total hospitalisations for COVID-19 and ICU-admissions were considered. Admissions were excluded if referring to patients who were positive but asymptomatic for COVID and suffered from diseases unrelated to the infection.
- Deaths: total number of deaths caused or contributed by SARS-CoV-2, linked to the cases included in the study and occurring up to 21 days (lastly up to 4th March) after diagnosis.
- Incidence of SARS-CoV-2 during whole winter 2021/22 was calculated for each district relating the cases amount to the number of inhabitants and expressed per 100,000 inhabitants.
- Hospitalisation Rates were assessed in the same way, relating both ordinary and ICU admissions to the inhabitant amount of each district and reported every 100,000 inhabitants.
- Hospitalisation proportion correspond to the number of both ordinary and ICU admissions related to the number of cases in the same district and expressed per 10,000 cases.
- Mortality and case fatality rate (CFR) were assessed relating the district’s death amount respectively per 100,000 inhabitants and per 10,000 cases.
2.4. Statistical Analyses
3. Results
3.1. Main Features of the Area
3.2. Territorial Characteristics and SARS-Cov-2 Epidemiology
| District Characteristics | Incidence* | Hospitalisation Rate* | ICUa Admission Rate* | Mortality* | Hospitalisation on cases** | ICUa Admission on cases** | Case fatality rate** | |
|---|---|---|---|---|---|---|---|---|
| Demographics | Inhabitants | -0.54 (0.015) |
0.19 (0.416) |
-0.27 (0.253) |
-0.17 (0.478) |
0.4 (0.077) |
-0.23 (0.332) |
-0.09 (0.696) |
| Population Density | -0.44 (0.050) |
-0.18 (0.435) |
-0.54 (0.014) |
-0.4 (0.077) |
0.03 (0.905) |
-0.52 (0.020) |
-0.36 (0.120) | |
| Social dynamics | Average Salary | 0.269 (0.250) |
−0.114 (0.630) |
0.093 (0.697) |
−0.289 (0.216) |
−0.205 (0.385) |
0.091 (0.704) |
−0.462 (0.040) |
| Winter Tourism | 0.54 (0.015) |
0.22 (0.359) |
0.29 (0.208) |
-0.11 (0.645) |
0.12 (0.627) |
0.29 (0.218) |
-0.2 (0.405) | |
| Health Services | Primary Series | -0.62 (0.004) |
0.01 (0.970) |
-0.4 (0.081) |
-0.43 (0.061) |
0.25 (0.298) |
-0.4 (0.080) |
-0.36 (0.123) |
| Booster Dose | -0.68 (0.001) |
0.11 (0.65) |
-0.38 (0.095) |
-0.34 (0.139) |
0.39 (0.091) |
-0.37 (0.11) |
-0.23 (0.326) | |
| Pharmacies (/km2) | -0.326 (0.161) |
-0.095 (0.690) |
-0.436 (0.055) |
0.109 (0.647) |
-0.424 (0.062) |
-0.401 (0.080) |
-0.363 (0.116) | |
| Geography | Average Altitude | 0.67 (0.001) |
-0.11 (0.631) |
0.23 (0.339) |
0.04 (0.865) |
-0.34 (0.141) |
0.19 (0.420) |
-0.05 (0.830) |
| District Characteristics |
Incidence* | Hospitalisation Rate* | ICUa Admission Rate* |
Mortality* | Hospitalisation on cases** | ICUa Admission on cases** |
Case fatality rate** |
|
|---|---|---|---|---|---|---|---|---|
| Health Services |
Big hospitals | 17298 (16035 - 18910) |
199 (177 - 230) |
20 (14 - 29) |
36 (34 - 37) |
116 (111 - 121) |
12 (8 - 16) |
19 (19 - 20) |
| Small hospitals | 17825 (16969 - 18479) |
160 (159 - 237) |
5.3 (4.8 - 24.7) |
33.9 (18.5 - 53) |
94 (87 - 133) |
3.1 (2.7 - 13.4) |
19 (10 - 31.2) |
|
| No hospitals | 18354 (17365 - 19661) |
139 (123 - 168) |
12.5 (0 - 23.1) |
34.6 (31.7 - 43.5) |
76 (68 - 97) |
6.2 (0 - 12.4) |
19.3 (18.5 - 23) |
|
| p-value | 0.707 | 0.054 | 0.739 | 0.993 | 0.01 | 0.683 | 0.987 | |
| Geography | Main Cities | 17298 (15958 - 19336) |
199 (176 - 239) |
19.9 (10.6 - 35.3) |
35.5 (32.9 - 37.1) |
116 (111 - 123) |
11.7 (5.9 - 18.9) |
19.1 (18.8 - 21.1) |
| Rural/ Towns | 18090 (17240 - 19510) |
159 (128 - 173) |
8.9 (1.9 - 23.9) |
34.3 (28.9 - 44.4) |
86 (70 - 97) |
4.7 (1.3 - 12.9) |
19.2 (17.2 - 24.4) |
|
| p-value | 0.617 | 0.029 | 0.554 | 0.963 | 0.005 | 0.437 | 0.963 | |
| Bordering with abroad | 19263 (18152 - 20118) |
221 (183 - 247) |
18.6 (8.7 - 36.4) |
36 (26.2 - 47) |
115 (95 - 130) |
9.8 (4.5 - 18.6) |
18.9 (14.4 - 23.5) |
|
| Not bordering | 17419 (16708 - 18974) |
159 (128 - 176) |
11.3 (1.9 - 22.8) |
34.7 (31.4 - 43.2) |
88 (70 - 98) |
5.8 (1.2 - 13.2) |
19.3 (18.6 - 23) |
|
| p-value | 0.178 | 0.022 | 0.335 | 0.82 | 0.05 | 0.437 | 0.82 | |
| Bordering with Italian regions | 18479 (16446 - 20475) |
132 (93 - 160) |
4.7 (0 - 19.5) |
33 (18.5 - 42.8) |
75 (59 - 84) |
2.7 (0 - 10.1) |
18.9 (10 - 22.1) |
|
| Not bordering | 17825 (17115 - 18589) |
177 (160 - 206) |
17.4 (4.8 - 33.7) |
34.8 (33.7 - 45.2) |
98 (94 - 112) |
9.4 (2.7 - 19.3) |
19.3 (18.8 - 23) |
|
| p-value | 0.643 | 0.006 | 0.275 | 0.351 | 0.003 | 0.211 | 0.351 | |
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Worldometer. Coronavirus Graphs: Worldwide Cases and Deaths. Available from: https://www.worldometers.
- Duong BV, Larpruenrudee P, Fang T, Hossain SI, Saha SC, Gu Y, et al. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant? Int J Environ Res Public Health. 2022;19(8):4586. [CrossRef]
- Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature. 2020;587(7835):610–2. [CrossRef]
- Landier J, Paireau J, Rebaudet S, Legendre E, Lehot L, Fontanet A, et al. Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic wave. Sci Rep. 2021;11:12756. [CrossRef]
- Smit AJ, Fitchett JM, Engelbrecht FA, Scholes RJ, Dzhivhuho G, Sweijd NA. Winter Is Coming: A Southern Hemisphere Perspective of the Environmental Drivers of SARS-CoV-2 and the Potential Seasonality of COVID-19. Int J Environ Res Public Health. 2020;17(16):5634. [CrossRef]
- Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. Ann Intern Med. 2020;M20-5008. [CrossRef]
- Vandelli V, Palandri L, Coratza P, Rizzi C, Ghinoi A, Righi E, et al. Conditioning factors in the spreading of Covid-19 – Does geography matter? Heliyon. 2024;10(3):e25810. [CrossRef]
- Open data Ministero della Salute. COVID-19 – Situazione Italia. Available from: https://opendatamds.maps.arcgis.com/apps/dashboards/0f1c9a02467b45a7b4ca12d8ba296596.
- Lorenzon A, Palandri L, Uguzzoni F, Cristofor CD, Lozza F, Poluzzi R, et al. Effectiveness of the SARS-CoV-2 Vaccination in Preventing Severe Disease-Related Outcomes: A Population-Based Study in the Italian Province of Bolzano (South Tyrol). Int J Public Health. 2024;69:1606792. [CrossRef]
- Elvidge AD, Renfrew IA. The Causes of Foehn Warming in the Lee of Mountains. Bulletin of the American Meteorological Society. 2016 Mar 1;97(3):455–66. [CrossRef]
- Alcock, A. The Protection of Regional Cultural Minorities and the Process of European Integration: the Example of South Tyrol. International Relations. 1992;11(1):17–36. [CrossRef]
- Wikipedia. South Tyrol. Available from: https://en.wikipedia.org/w/index.php?title=South_Tyrol&oldid=1181193098.
- Millet GP, Debevec T, Brocherie F, Burtscher M, Burtscher J. Altitude and COVID-19: Friend or foe? A narrative review. Physiol Rep. 2021;8(24):e14615. [CrossRef]
- Weaver AK, Head JR, Gould CF, Carlton EJ, Remais JV. Environmental Factors Influencing COVID-19 Incidence and Severity. Annu Rev Public Health. 2022;43:271–91. [CrossRef]
- Pun M, Turner R, Strapazzon G, Brugger H, Swenson ER. Lower Incidence of COVID-19 at High Altitude: Facts and Confounders. High Alt Med Biol. 2020;21(3):217–22. [CrossRef]
- Clemente-Suárez VJ, Hormeño-Holgado A, Jiménez M, Benitez-Agudelo JC, Navarro-Jiménez E, Perez-Palencia N, et al. Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic. Vaccines (Basel). 2020;8(2):236. [CrossRef]
- Azienda Sanitaria dell’Alto Adige. Home page. Available from: https://www.asdaa.
- Provincia autonoma di Bolzano - Alto Adige. Istituto provinciale di statistica. Available from: https://astat.provincia.bz.it/it/default.
- Frei A, Kaufmann M, Amati R, Butty Dettwiler A, von Wyl V, Annoni AM, et al. Development of hybrid immunity during a period of high incidence of Omicron infections. International Journal of Epidemiology. 2023;52(6):1696–707. [CrossRef]
- Gazzetta Ufficiale [Internet]. [cited 2023 Oct 26]. Available from: https://www.gazzettaufficiale.it/eli/id/2022/03/04/22A01497/sg.
- Provincia autonoma di Bolzano - Alto Adige. In Alto Adige è in costante aumento il tasso di copertura vaccinale. Available from: https://news.provincia.bz.it/it/news-archive/663463.
- Gazzetta Ufficiale. Decreto del Presidente del Consiglio dei Ministri del 17 giugno 2021. Available from: https://www.gazzettaufficiale.it/eli/id/2021/06/17/21A03739/sg.
- Jamovi. Open statistical software for the desktop and cloud. Available from: https://cloud.jamovi.
- Palandri, L.; Rizzi, C.; Vandelli, V.; Filippini, T.; Ghinoi, A.; Carrozzi, G.; Girolamo, G.D.; Morlini, I.; Coratza, P.; Giovannetti, E.; et al. Environmental, Climatic, Socio-Economic Factors and Non-Pharmacological Interventions: A Comprehensive Four-Domain Risk Assessment of COVID-19 Hospitalization and Death in Northern Italy. International Journal of Hygiene and Environmental Health 2025, 263, 114471. [CrossRef]
- Devaux CA, Raoult D.The impact of COVID-19 on populations living at high altitude: Role of hypoxia-inducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication. Front Physiol. 2022;13:960308. [CrossRef]
- Fiolet T, Kherabi Y, MacDonald CJ, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022;28(2):202–21. [CrossRef]
- Reynolds L, Dewey C, Asfour G, Little M. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Frontiers in Public Health. 2023;11. [CrossRef]
- Thirión-Romero I, Fernández-Plata R, Pérez-Kawabe M, Meza-Meneses PA, Castro-Fuentes CA, Rivera-Martínez NE, et al. SARS-CoV-2 Vaccine Effectiveness in Hospitalized Patients: A Multicenter Test-Negative Case–Control Study. Vaccines. 2023 Dec;11(12):1779. [CrossRef]
- Braeye T, Catteau L, Brondeel R, van Loenhout JAF, Proesmans K, Cornelissen L, et al. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021–2022. Vaccine. 2023;41(20):3292–300. [CrossRef]
- Lugli, C.; Ferrari, E.; Filippini, T.; Corsini, A.G.; Odone, A.; Vinceti, M.; Righi, E.; Palandri, L. It’s (Not) Rocket Science: Public Health Communication Experience as Expressed by Participants to an International Workshop. Popul. Med. 2024, 6, 1–7. [CrossRef]
- Palandri, L.; Urbano, T.; Pezzuoli, C.; Miselli, F.; Caraffi, R.; Filippini, T.; Bargellini, A.; Righi, E.; Mazzi, D.; Vigezzi, G.P.; et al. The Key Role of Public Health in Renovating Italian Biomedical Doctoral Programs. Ann Ig 2024. [CrossRef]
- Provincia autonoma di Bolzano - Alto Adige. Download dati – Meteo. Available from: https://meteo.provincia.bz.it/download-dati.
- Palandri, L.; Morgado, M.; Colucci, M.E.; Affanni, P.; Zoni, R.; Mezzetta, S.; Bizzarro, A.; Veronesi, L. Reorganization of Active Surveillance of Acute Flaccid Paralysis (AFP) in Emilia-Romagna, Italy: A Two-Step Public Health Intervention. Acta Biomed 2020, 91, 85–91. [CrossRef]
- Ferrari, E.; Scannavini, P.; Palandri, L.; Fabbri, E.; Tura, G.; Bedosti, C.; Zanni, A.; Mosci, D.; Righi, E.; Vecchi, E. Training in Infection Prevention and Control: Survey on the Volume and on the Learning Demands of Healthcare-Associated Infections Control Figures in the Emilia-Romagna Region (Northern Italy). Ann Ig 2024. [CrossRef]
- L’Adige.it. Coronavirus in Alto Adige, la situazione sta precipitando: altri 2 morti e 255 nuovi contagi nelle ultime 24 ore - Alto Adige - Südtirol. Available from: https://www.ladige.it/territori/alto-adige-s%C3%BCdtirol/2021/11/04/covid-in-alto-adige-la-situazione-precipita-altri-2-morti-e-255-nuovi-contagi-1.3045707.
- Gazzetta Ufficiale. Legge 21 gennaio 2022, n. 3. Available from: https://www.gazzettaufficiale.it/eli/id/2022/01/25/22G00006/sg.


| Incidence | Estimate | Confidence Interval | Standardised estimate | p-value | Model adjusted R² |
|---|---|---|---|---|---|
| Intercept | 23.24 | (15.13 - 31.34) | <0.001 | 0.60 | |
| Vaccination coverage (booster dose) | -0.17 | (-0.32 - 0.02) | -0.44 | 0.033 | p-value |
| Average Altitude (km) | 1.79 | (-1.13 - 4.72) | 0.34 | 0.212 | 0.001 |
| Winter Tourists (*100,000) | 0.12 | (-0.03 - 0.26) | 0.33 | 0.100 | |
| Population density (/hectare) | 0.03 | (-0.13 - 0.19) | 0.08 | 0.685 | |
| Hospitalisation proportion on cases | Estimate | Confidence Interval | Standardised estimate | p-value | Model adjusted R² |
| Intercept | 73.93 | (-8.63 - 156.48) | 0.075 | 0.61 | |
| Vaccination coverage (booster dose) | 0.29 | (-1.64 - 2.22) | 0.06 | 0.749 | p-value |
| Hospital absence/small/big | 12.37 | (0.85 - 23.89) | 0.42 | 0.037 | 0.002 |
| Bordering with abroad | 17.88 | (-2.16 - 37.92) | 0.74 | 0.076 | |
| Bordering with other Italian Regions | -20.72 | (-37.05 - -4.39) | -0.86 | 0.017 | |
| Pharmacies density (/km2) | -1.67 | (-88.42 - 85.09) | -0.01 | 0.968 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).